Finance

Lists
Why is KLRS down 5,26%?
Dive Deeper
KLRS:NASDAQ
Kalaris Therapeutics Inc
US$2,70
-5,26%
(-0,15) 1D
US$2,70
0,00% (0,00)
After hours
Closed: 2 ຕ.ລ., 16 ໂມງ 0 ນາທີ 01 ວິນາທີ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KLRS...
Open
US$2,90
High
US$2,90
Low
US$2,51
Mkt. cap
64,27 ລ້ານ
Avg. vol.
64,48 ພັນ
Volume
235,90 ພັນ
52-wk high
US$11,88
52-wk low
US$2,51
EPS
US$-2,09
Beta
0,42
Shares outstanding
23,80 ລ້ານ
No. of employees
20
Open
US$2,90
High
US$2,90
Low
US$2,51
Mkt. cap
64,27 ລ້ານ
Avg. vol.
64,48 ພັນ
Volume
235,90 ພັນ
52-wk high
US$11,88
52-wk low
US$2,51
EPS
US$-2,09
Beta
0,42
Shares outstanding
23,80 ລ້ານ
No. of employees
20
News stories
From web sources and news partners
The Motley Fool
The Motley Fool
·
8 ນາທີກ່ອນ
The S&P 500 Hasn't Looked This Cheap Based on a Popular Metric in Decades. Should You Buy Stocks Now?
Stock Traders Daily
Stock Traders Daily
·
4 ຊົ່ວໂມງກ່ອນ
(TDIV) Price Dynamics and Execution-Aware Positioning
Simply Wall Street
Simply Wall Street
·
1 ຊົ່ວໂມງກ່ອນ
3 Consumer Staples Stocks Tied To Rising Pet Care Spending
Business Insider
Business Insider
·
1 ມື້ກ່ອນ
The NYSE's Most Famous Floor Trader Says AI Can't Take His Job
About Kalaris Therapeutics Inc
CEO-
Employees20
Founded2019
HeadquartersBerkeley Heights, ນິວເຈີຊີ, ສະຫະລັດ
SectorBiotechnology
Websitekalaristx.com
Analyst ratings
Based on 3 analysts giving stock ratings to KLRS in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for KLRS in the last 3 months.
Highest
Current US$2,70
US$17,00 (+529,63%)
Average
US$15,50 (+474,07%)
Lowest
US$14,00 (+418,52%)
Analyst
Recommendation
Action
Price target
Projected
Date
Judah Frommer
Morgan Stanley
Buy
Reiterated
US$14,00
+418,5%
08/12/2026
Yun Zhong
Wedbush
Buy
Reiterated
US$17,00
+529,6%
08/11/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
08/11/2026
Tara Bancroft
TD Cowen
Buy
Initiated
-
-
06/15/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
US$25,00
+825,9%
05/13/2026
Biren Amin
Piper Sandler
Hold
Maintained
US$7,00
+159,3%
03/30/2026
Daniil Gataulin
Chardan Capital
Buy
Initiated
US$19,00
+603,7%
12/23/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
9,13 ລ້ານ
7,16 ລ້ານ
7,57 ລ້ານ
9,02 ລ້ານ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,62 ລ້ານ
3,64 ລ້ານ
4,26 ລ້ານ
3,37 ລ້ານ
Operating expense
12,74 ລ້ານ
10,80 ລ້ານ
11,83 ລ້ານ
12,39 ລ້ານ
Total operating expenses
12,74 ລ້ານ
10,80 ລ້ານ
11,83 ລ້ານ
12,39 ລ້ານ
Operating income
-12,74 ລ້ານ
-10,80 ລ້ານ
-11,83 ລ້ານ
-12,39 ລ້ານ
Other non operating income
847,00 ພັນ
803,00 ພັນ
977,00 ພັນ
871,00 ພັນ
EBT including unusual items
-11,89 ລ້ານ
-10,00 ລ້ານ
-10,86 ລ້ານ
-11,52 ລ້ານ
EBT excluding unusual items
-11,89 ລ້ານ
-10,00 ລ້ານ
-10,86 ລ້ານ
-11,52 ລ້ານ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-11,89 ລ້ານ
-10,00 ລ້ານ
-10,86 ລ້ານ
-11,52 ລ້ານ
Net profit margin
-
-
-
-
Earnings per share
-0,64
-0,44
-0,46
-0,48
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-12,74 ລ້ານ
-10,79 ລ້ານ
-11,82 ລ້ານ
-12,38 ລ້ານ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
ແອັບຂອງ Google